Navigation Links
Laureate Biopharma Appoints Les Mintzmyer, Vice President, Operations
Date:2/14/2012

PRINCETON, N.J., Feb. 14, 2012 /PRNewswire/ -- Laureate Biopharmaceutical Services, Inc., a full-service biopharmaceutical contract development and manufacturing organization, today announced the appointment of Les Mintzmyer as Vice President, Operations. He will be responsible for continuing Laureate's transition to a full-scale commercial manufacturing operation. This will include preparing for upcoming pre-approval inspections at Laureate's Princeton facility, expanding production capacity with the commissioning of a new 2000L single-use bioreactor train, expanding Laureate's filling business in its freshly renovated filling facility, and planning for a new manufacturing facility. "Les brings a wealth of experience in managing every aspect of biopharmaceutical manufacturing operations," said Michael A. Griffith, Chief Executive Officer. "His combination of technical acuity and management savvy makes Les uniquely qualified to lead the continued expansion of our manufacturing operations to build our business."

(Logo: http://photos.prnewswire.com/prnh/20120214/PH53290LOGO )

Mr. Mintzmyer has more than 25 years of experience commissioning and operating full-scale biopharmaceutical manufacturing operations. Prior to joining Laureate as Vice President, Operations, Mr. Mintzmyer has served as Vice President, Manufacturing Operations for Avid BioServices, Senior Director, Manufacturing Operations at ImClone; Director, Operational Excellence and Director, Manufacturing for Genentech; and Director of Manufacturing at Bristol-Myers Squibb. As Director of Manufacturing at Bristol-Myers Squibb, he led the creation of a biologics manufacturing capability that obtained FDA licensure and launched Orencia® in 2005. Mr. Mintzmyer earned a Master of Science in Chemical Engineering and a Bachelor of Science in Chemical Engineering from Colorado State University, and a Bachelor of Science
'/>"/>

SOURCE Laureate Biopharmaceutical Services, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Laureate Pharma to Add More Manufacturing Capacity
2. Laureate Announces Manufacturing Agreement with Tolerx
3. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
4. Laureate Pharma Honored as Emerging Life Sciences Company of the Year
5. Nobel Laureates to Speak at Keystone Symposia RNA Silencing Conference
6. US Oncology Named 2009 Laureate by IDG Computerworld Honors Program
7. Nobel Laureate Lee Hartwell to Retire as President and Director of Fred Hutchinson Cancer Research Center in 2010
8. Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development
9. Laureate Pharma Elects New Board Member
10. Thomson Reuters Predicts Nobel Laureates
11. Laureate Pharma Welcomes Three New Members to Business Development Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... NEW YORK , Oct. 20, 2014 /PRNewswire/ ... of their experimental ZMapp™ antibody therapeutic to fight ... of how difficult and time-consuming the production of ... healthcare market research publisher said that while some ... cycle of this compound, those with industry knowledge ...
(Date:10/20/2014)... MENLO PARK, Calif. , Oct. 20, 2014 ... announced today that the Company has signed a ... Institute of Regenerative Medicine (CIRM), effective October 1, ... of Clinical Development payments and the release of ... $14.3 million CIRM grant award for clinical development ...
(Date:10/20/2014)... VIENNA , October 20, 2014 ... of gastrointestinal (GI) disorders and the delivery of care ... liver diseases and worrying inequalities in the provision of ... survey, which was commissioned by United European Gastroenterology (UEG), ... greater political and public awareness of the burden of ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... David Meyer to our team as the Vice President of ... the executive leadership in building upon the HumanTouch health strategy. ... (IT) experience and expertise HumanTouch has been cultivating for 15 ... more than 20 years of diverse experience in the health ...
... 2011 PharmAthene, Inc. (NYSE Amex: PIP ... the Russell Global Index and the Russell 3000 Index ... and global equity indexes on June 24, 2011.  The ... largest U.S. companies based on total market capitalization.  The ...
... 27, 2011 Chimerix, Inc., a pharmaceutical ... with the Biomedical Advanced Research and Development Authority (BARDA) ... Services (HHS) that will resolve the Government Accountability Office ... to SIGA Technologies, Inc. for the development and delivery ...
Cached Biology Technology:HumanTouch Welcomes David Meyer as Vice President of HumanTouch's new Health Solutions Division 2PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index 2PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index 3PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index 4Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract 2Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract 3Chimerix and BARDA Reach Agreement Ending GAO Review of Smallpox Antiviral Contract 4
(Date:10/18/2014)... genetic conditions, a certain type of exome sequencing method ... traditional molecular diagnostic methods, according to a study appearing ... to coincide with the American Society of Human Genetics ... region of the genome (the complete set of genes ... has been rapidly applied in research settings and recent ...
(Date:10/17/2014)... German . ... When treating overdoses, doctors are often limited to supportive therapy ... is a combination of drugs involved. So what can be ... grandmother,s pills? ETH professor Jean-Christophe Leroux from the Institute of ... to this question. "The task was to develop an agent ...
(Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Emergency aid for overdoses 2Emergency aid for overdoses 3Cryptic clues drive new theory of bowel cancer development 2
... (Garrison NY) A Hastings Center workshop examining moral issues ... J. Craig Venter Group announced that it had created ... biology certainly raises deep philosophical and moral questions about ... a Hastings Center scholar who is managing the project. ...
... polluting some of California,s most popular beaches. Yet few ... systems and coastal contamination. Now, in ... have tracked a plume of polluted groundwater from a ... beaches. The researchers say their findings could be an ...
... ancient frogs may soon be mined to extinction, if the ... for mining go ahead. The primitive Archey,s frog ( ... are two of the species that inhabit the area of ... mining is planned to take place. Archey,s frog is ...
Cached Biology News:Stanford scientists track polluted groundwater to the sea 2Stanford scientists track polluted groundwater to the sea 3Stanford scientists track polluted groundwater to the sea 4Prehistoric frogs face extinction 2
... (GST) is commonly used as a fusion ... (1). The GSTTag sequence has been reported ... cases the solubility of its fusion partners. ... form, GSTTag fusion proteins can be purified ...
... The Bio-Stack is compatible with BioTeks ... Speed, ease of use and walkaway ... microplate process. When used with the ... dispenser, the Bio-Stacks small footprint fits ...
... for the use of small interfering RNA ... the RNA interference,(RNAi) pathway have generated tremendous ... fields. siRNA for experimental use can be,synthesized ... then transfected into the target cells in ...
... scientists who have access to microarray scanning and ... with proteins from S&Ss antibody menu or from ... performed by the customer. Its as easy as ... with an expert and define the best adapted ...
Biology Products: